| Epstein-Barr virus infection |
1.90 |
5.16e-2 |
189/202 (93.56%) |
ISG15;BTK;BLNK;...
|
| Spliceosome |
1.84 |
5.16e-2 |
101/150 (67.33%) |
THOC2;HNRNPM;RBM25;...
|
| Herpes simplex virus 1 infection |
1.80 |
6.19e-2 |
165/498 (33.13%) |
DDX58;OAS3;OAS2;...
|
| B cell receptor signaling pathway |
1.75 |
7.22e-2 |
71/81 (87.65%) |
PPP3CA;BTK;BLNK;...
|
| Antigen processing and presentation |
1.75 |
5.98e-2 |
60/78 (76.92%) |
TAP1;HLA-B;HSPA5;...
|
| Kaposi sarcoma-associated herpesvirus infection |
1.68 |
1.05e-1 |
172/193 (89.12%) |
PPP3CA;LEF1;E2F2;...
|
| Primary immunodeficiency |
1.67 |
9.43e-2 |
33/38 (86.84%) |
BTK;BLNK;TAP1;...
|
| Prostate cancer |
1.67 |
8.25e-2 |
93/97 (95.88%) |
LEF1;E2F2;CDKN1B;...
|
| Sulfur metabolism |
1.59 |
1.78e-1 |
9/10 (90%) |
PAPSS1;SELENBP1
|
| Taurine and hypotaurine metabolism |
1.56 |
2.01e-1 |
8/11 (72.73%) |
CSAD;GAD1;BAAT
|
| Signaling pathways regulating pluripotency of stem cell... |
1.55 |
2.20e-1 |
110/143 (76.92%) |
ID3;TBX3;SMAD3;...
|
| Hepatitis C |
1.54 |
2.06e-1 |
139/157 (88.54%) |
IFIT1;MX1;E2F2;...
|
| RNA degradation |
1.52 |
2.13e-1 |
53/79 (67.09%) |
CNOT4;PFKL;BTG3;...
|
| RIG-I-like receptor signaling pathway |
1.49 |
2.67e-1 |
64/70 (91.43%) |
ISG15;DDX58;IRF7;...
|
| Influenza A |
1.49 |
2.54e-1 |
156/172 (90.7%) |
MX1;DDX58;OAS3;...
|
| Gastric acid secretion |
1.48 |
2.52e-1 |
63/76 (82.89%) |
GNAS;EZR;PRKCB;...
|
| Homologous recombination |
1.46 |
2.77e-1 |
35/41 (85.37%) |
BARD1;RBBP8;NBN;...
|
| MicroRNAs in cancer |
1.45 |
2.90e-1 |
146/310 (47.1%) |
E2F2;EZR;CDKN1B;...
|
| Hippo signaling pathway |
1.44 |
2.88e-1 |
120/186 (64.52%) |
LEF1;DLG5;SMAD3;...
|
| Leishmaniasis |
1.44 |
2.77e-1 |
67/77 (87.01%) |
MARCKSL1;PRKCB;TAB2;...
|
| Butanoate metabolism |
1.42 |
3.09e-1 |
23/28 (82.14%) |
ALDH5A1;ACAT2;GAD1;...
|
| Coronavirus disease |
1.42 |
3.00e-1 |
215/232 (92.67%) |
ISG15;MX1;CFD;...
|
| Human papillomavirus infection |
1.41 |
3.12e-1 |
284/331 (85.8%) |
ISG15;MX1;GNAS;...
|
| Breast cancer |
1.40 |
3.22e-1 |
119/147 (80.95%) |
LEF1;E2F2;FZD10;...
|
| Type I diabetes mellitus |
1.39 |
3.22e-1 |
38/43 (88.37%) |
HLA-B;GAD1;HLA-DMB;...
|
| Protein digestion and absorption |
1.39 |
3.12e-1 |
78/103 (75.73%) |
COL5A2;COL7A1;SLC7A7;...
|
| Phosphonate and phosphinate metabolism |
1.39 |
3.03e-1 |
5/6 (83.33%) |
CHPT1;CEPT1
|
| Wnt signaling pathway |
1.38 |
3.03e-1 |
124/166 (74.7%) |
PPP3CA;LEF1;TBL1XR1;...
|
| Hepatocellular carcinoma |
1.38 |
2.94e-1 |
135/168 (80.36%) |
LEF1;E2F2;GSTM3;...
|
| Allograft rejection |
1.37 |
3.20e-1 |
32/38 (84.21%) |
HLA-B;HLA-DMB;HLA-E;...
|
| Mitophagy |
-1.21 |
5.96e-1 |
56/68 (82.35%) |
MFN2;BNIP3;TBC1D17;...
|
| Dopaminergic synapse |
-1.22 |
5.68e-1 |
115/132 (87.12%) |
CLOCK;DRD5;AKT2;...
|
| Fatty acid elongation |
-1.23 |
5.72e-1 |
19/27 (70.37%) |
HACD1;ELOVL5;HSD17B12;...
|
| cAMP signaling pathway |
-1.23 |
5.73e-1 |
188/216 (87.04%) |
AMH;PDE4C;HTR6;...
|
| Colorectal cancer |
-1.24 |
5.71e-1 |
84/86 (97.67%) |
KRAS;MAPK10;AXIN1;...
|
| Complement and coagulation cascades |
-1.26 |
5.12e-1 |
76/85 (89.41%) |
PROCR;C4BPB;MBL2;...
|
| JAK-STAT signaling pathway |
-1.27 |
5.19e-1 |
146/162 (90.12%) |
AKT2;GHR;SOCS6;...
|
| Galactose metabolism |
-1.27 |
5.38e-1 |
26/31 (83.87%) |
PFKM;GCK;GALE;...
|
| Parkinson disease |
-1.27 |
5.49e-1 |
176/249 (70.68%) |
PSMD6;CYC1;BAX;...
|
| Citrate cycle (TCA cycle) |
-1.27 |
5.65e-1 |
30/30 (100%) |
MDH1;SDHC;OGDH;...
|
| Hematopoietic cell lineage |
-1.27 |
5.83e-1 |
90/99 (90.91%) |
ITGAM;CD3G;CD33;...
|
| Aldosterone synthesis and secretion |
-1.28 |
5.72e-1 |
85/98 (86.73%) |
CREB5;PRKACA;POMC;...
|
| Oxidative phosphorylation |
-1.30 |
5.17e-1 |
93/133 (69.92%) |
ATP6V0E1;ATP5MC3;ATP5PF;...
|
| Tryptophan metabolism |
-1.31 |
5.32e-1 |
35/42 (83.33%) |
ALDH8A1;TDO2;CYP1B1;...
|
| Tyrosine metabolism |
-1.32 |
5.32e-1 |
30/36 (83.33%) |
TYR;HGD;ADH1B;...
|
| Huntington disease |
-1.32 |
5.39e-1 |
233/306 (76.14%) |
GRIN2B;ATP5MC3;PLCB1;...
|
| Taste transduction |
-1.33 |
5.34e-1 |
61/86 (70.93%) |
HTR1D;TAS2R1;CACNA1C;...
|
| Prion disease |
-1.33 |
5.59e-1 |
209/273 (76.56%) |
GRIN2D;PSMD6;CYC1;...
|
| Cortisol synthesis and secretion |
-1.35 |
5.20e-1 |
58/65 (89.23%) |
CREB5;PRKACA;POMC;...
|
| Cytokine-cytokine receptor interaction |
-1.35 |
5.49e-1 |
246/295 (83.39%) |
IL36G;CSH1;NGF;...
|
| RNA polymerase |
-1.36 |
5.76e-1 |
23/31 (74.19%) |
POLR2L;POLR3F;POLR3C;...
|
| Non-alcoholic fatty liver disease |
-1.44 |
4.51e-1 |
126/155 (81.29%) |
CYC1;BAX;CDC42;...
|
| Neuroactive ligand-receptor interaction |
-1.47 |
3.80e-1 |
294/341 (86.22%) |
BRS3;GLRA1;SSTR3;...
|
| Ubiquinone and other terpenoid-quinone biosynthesis |
-1.53 |
2.73e-1 |
9/11 (81.82%) |
HPD;COQ2;GGCX;...
|
| Adrenergic signaling in cardiomyocytes |
-1.61 |
1.71e-1 |
130/150 (86.67%) |
CACNG2;CACNA2D1;PPP1R1A;...
|
| Hypertrophic cardiomyopathy |
-1.64 |
1.19e-1 |
81/90 (90%) |
ITGB8;CACNB4;ITGB1;...
|
| Ribosome |
-1.65 |
1.37e-1 |
113/158 (71.52%) |
MRPL24;RPL18;RPL22;...
|
| Dilated cardiomyopathy |
-1.66 |
1.41e-1 |
86/96 (89.58%) |
CACNG1;SLC8A2;MYL3;...
|
| Cardiac muscle contraction |
-1.72 |
1.25e-1 |
64/87 (73.56%) |
TRDN;CACNG1;SLC8A2;...
|
| Steroid hormone biosynthesis |
-1.76 |
1.44e-1 |
43/61 (70.49%) |
UGT2A3;AKR1D1;CYP1A2;...
|
